Do tofacitinib generics exhibit conventional synthetic disease-modifying anti-rheumatic drug and non-steroidal anti-inflammatory drug-sparing ability in the management of axial spondyloarthritis

dc.contributor.author	Arvind Ganapati
dc.contributor.author	Suvrat Arya
dc.contributor.author	Nikhil Gupta
dc.contributor.author	Nikhil Gupta
dc.contributor.author	Chebbi, Pramod Prahlad
dc.contributor.author	Daisy Doley
dc.contributor.author	Jeevanagi, Sachin R.
dc.contributor.author	Rahul Sahu
dc.contributor.author	Mandal, Santosh K.
dc.date.accessioned	2024-07-23T11:17:48Z
dc.date.available	2024-07-23T11:17:48Z
dc.date.issued	2023-10
dc.identifier.citation	Cureus. 2023 Oct; 15(10): 1-14.	en_US
dc.identifier.issn	2168-8184
dc.identifier.uri	http://dspace.sdmmedicalcollege.org:8080/xmlui/handle/123456789/2255
dc.language.iso	en	en_US
dc.publisher	Cureus, Inc.	en_US
dc.subject	Sulfasalazine	en_US
dc.subject	Axial spondyloarthritis	en_US
dc.subject	Ankylosing spondylitis	en_US
dc.title	Do tofacitinib generics exhibit conventional synthetic disease-modifying anti-rheumatic drug and non-steroidal anti-inflammatory drug-sparing ability in the management of axial spondyloarthritis	en_US
dc.type	Article	en_US